Biomedical subjects

T K Kihara

Publications and source records attributed to T K Kihara.

4 recordsLinked to original sources

PubMed2000

Opioid growth factor modulates angiogenesis.

OBJECTIVE: Induced angiogenesis has recently been attempted as a therapeutic modality in patients with occlusive arterial atherosclerotic disease. We investigated the possible role of endogenous opioids in the modulation of angiogenesis. METHODS: Chick chorioallantoic membrane was used as an in vivo model to study angiogenesis. Fertilized chick eggs were incubated for 3 days, explanted, and incubated for an additional 2 days. Three-millimeter methylcellulose disks were placed on the surface of the chorioallantoic membrane; each disk contained opioid growth factor ([Met(5)]-enkephalin; 5 microgram), the short-acting opioid receptor antagonist naloxone (5 microgram), opioid growth factor and naloxone together (5 microgram of each), the long-acting opioid antagonist naltrexone (5 microgram), or distilled water (control). A second series of experiments was performed with distilled water, the angiogenic inhibitor retinoic acid (1 microgram), and vascular endothelial growth factor (1 microgram) to further evaluate our model. The developing vasculature was imaged 2 days later with a digital camera and exported to a computer for image analysis. Total number of blood vessels, total vessel length, and mean vessel length were measured within a 100-mm(2) region surrounding each applied disk. Immunocytochemical analysis was performed with antibodies directed against opioid growth factor and its receptor (OGFr). RESULTS: Opioid growth factor had a significant inhibitory effect on angiogenesis, both the number of blood vessels and the total vessel length being decreased (by 35% and 20%, respectively) in comparison with control levels (P <.005). The simultaneous addition of naloxone and opioid growth factor had no effect on blood vessel growth, nor did naloxone alone. Chorioallantoic membranes exposed to naltrexone displayed increases of 51% and 24% in blood vessel number and length, respectively, in comparison with control specimens (P <.005). These results indicate that the opioid growth factor effects are receptor mediated and tonically active. Immunocytochemistry demonstrated the presence of both opioid growth factor and OGFr within the endothelial cells and mesenchymal cells of the developing chorioallantoic membrane vessel wall. Retinoic acid significantly reduced the number and the total length of blood vessels, whereas vascular endothelial growth factor increased both the number and the length of blood vessels in comparison with the controls (P <.0001). The magnitude of opioid growth factor's effects were comparable to those seen with retinoic acid, whereas inhibition of opioid growth factor with naltrexone induced an increase in total vessel length comparable to that for vascular endothelial growth factor. CONCLUSIONS: These results demonstrate for the first time that endogenous opioids modulate in vivo angiogenesis. Opioid growth factor is a tonically active peptide that has a receptor-mediated action in regulating angiogenesis in developing endothelial and mesenchymal vascular cells.

Allantois↗

PubMed1999

Risk factors and outcomes following revascularization for chronic mesenteric ischemia.

Revascularization for chronic mesenteric ischemia is an infrequent vascular procedure whose objective long-term patency results have been described in relatively few patients. We reviewed our experience with such procedures and report on the objective and symptomatic long-term results. We retrospectively reviewed a consecutive series of 42 patients who underwent mesenteric arterial reconstruction of 66 vessels during an 11-year period from 1986 to 1997. All patients were treated for symptomatic chronic mesenteric ischemia. The results support the clinical efficacy and durability of visceral artery bypass procedures for patients with symptomatic chronic mesenteric ischemia. Patency rates for females were better than for males independent of graft type.

Angioplasty↗

PubMed1999

A national survey of practice patterns in the noninvasive diagnosis of deep venous thrombosis.

PURPOSE: Recent studies have recommended unilateral venous duplex scanning for the diagnosis of deep venous thrombosis (DVT) in patients who are unilaterally symptomatic. Vascular laboratory accreditation standards, however, imply that bilateral leg scanning should be performed. We examined whether actual practice patterns have evolved toward limited unilateral scanning in such patients. METHODS: A questionnaire was mailed to all 808 vascular laboratories in the United States that were accredited by the Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL). To encourage candid responses, the questionnaires were numerically coded and confidentiality was assured. RESULTS: A total of 608 questionnaires (75%) were completed and returned. Most of the respondents (442; 73%) were either community-hospital or office-based laboratories, and the remaining 163 (27%) were university or affiliated-hospital laboratories. Most of the laboratories (460; 76%) had been in existence for 9 years or more, and 65% had been ICAVL-accredited in venous studies for 3 years or more. Board-certified vascular surgeons were the medical directors in 54% of the laboratories. Duplex ultrasound scanning was the diagnostic method used by 98% of the laboratories. In patients with unilateral symptoms, 75% of the laboratories did not routinely scan both legs for DVT. A large majority (75%) believe that bilateral scanning is not clinically indicated. Only 57 laboratories (14%) recalled having patients return with a DVT in the previously unscanned leg, with 93% of these laboratories reporting between one and five such patients. This observation correlated with larger volumes of venous studies performed by those laboratories (P <.05). Similarly, only 52 laboratories (12%) recalled having patients return with subsequent pulmonary emboli. Of these laboratories, only five reported proximal DVT in the previously unscanned legs of such patients. Of all these laboratories, therefore, only 1% (5 of 443) have potentially missed the diagnosis of a DVT that caused a preventable pulmonary embolus with such a policy. Among those laboratories that always perform bilateral examinations, 41% do so because of habit. Most (61%) of the laboratories that perform bilateral scanning would do unilateral scanning if it were specifically approved by ICAVL. CONCLUSION: Three quarters of the ICAVL-accredited vascular laboratories perform limited single-extremity scanning for the diagnosis of DVT in patients with unilateral symptoms. This broad clinical experience suggests that this practice is widespread in selected patients. Clinical protocols should be established to provide guidelines for local laboratory implementation.

Health Care Surveys↗

PubMed1987

Immunochemical studies of Lolium perenne (rye grass) pollen allergens, Lol p I, II, and III.

It was reported earlier that human immune responses to three perennial rye grass (Lolium perenne) pollen allergens, Lol p I, II, and III, are associated with histocompatibility leukocyte antigen (HLA)-DR3. Rye-allergic people are often concordantly sensitive to all three of these allergens. Since earlier studies suggested that these antigens are non-cross-reactive, their immunologic relatedness by double antibody radioimmunoassay (DARIA) was studied in order to understand further the immunochemical basis for the concordant recognition of the three allergens. Direct binding DARIA studies were performed with human sera from 189 allergic subjects. Inhibition DARIA studies were carried out with 17 human sera from grass-allergic patients who were on grass immunotherapy, one goat anti-serum, and six rabbit antisera. None of the sera detected any significant degree of two-way cross-reactivity between Lol p I and II, or between Lol p I and III. However, the degree of two-way cross-reactivity between Lol p II and III exhibited by individual human and animal antisera varied between undetectable and 100%. In general, the degree of cross-reactivity between Lol p II and III was higher among human sera than among animal sera. Taken together with earlier findings that antibody responses to Lol p I, II and III are associated with HLA-HDR3, and that most Lol p II and III responders are also Lol p I responders, but not vice versa, our present results suggest the following: the HLA-DR3-encoded Ia molecule recognizes a similar immunodominant Ia recognition site (agretope) shared between Lol p I and Lol p II and/or III; in addition, Lol p I appears to contain unique Ia recognition site(s) not present in Lol p II and III. However, further epitope analyses are required to investigate these possibilities.

Allergens↗